首页> 外文OA文献 >PIN73 Estimating the cost-Effectiveness of 12 weeks of treatment with Daclatasvir+Sofosbuvir In Patients Chronically Infected With hcv Genotype 3

【2h】

PIN73 Estimating the cost-Effectiveness of 12 weeks of treatment with Daclatasvir+Sofosbuvir In Patients Chronically Infected With hcv Genotype 3

机译：PIN73估计达卡他韦+索福布韦治疗慢性感染hcv基因型3的患者12周的成本效益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
McEwan P.; Ward T.; Webster S.; Kalsekar A.; Brenner M.; Yuan Y.;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin [J] . Agarwal Kosh, Schultz Michael, Pianko Stephen, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Sofosbuvir Plus Peginterferon Plus利韦利林在基因型中为12周，3个HCV感染患者和治疗经验丰富的肝硬化患者2 HCV在Sofosbuvir Plus利巴韦林的16或24周后没有达到SVR
2. 8 weeks treatment under real life conditions with Ledipasvir/Sofosbuvir in HIV co-infected treatment-naive HCV genotype 1 patients demonstrates similar results to mono-infected HCV patients: data from the German Hepatitis C-Registry (DHC-R) [J] . Buggisch Peter, Boeker Klaus H., Guenther Rainer, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：8周治疗在现实生活条件下，艾滋病病毒治疗治疗 - 幼稚HCV基因型1例患者对单次感染的HCV患者进行了类似的结果：来自德国丙型肝炎的数据（DHC-R）数据
3. Efficacy of 12 or 18?weeks of elbasvir plus grazoprevir with ribavirin in treatment‐na?ve, noncirrhotic HCV HCV genotype 3‐infected patients [J] . Gane E., Nahass R., Luketic V., Journal of viral hepatitis. . 2017,第10期

机译：疗效为12或18周的Elbasvir Plus Grazophir与利巴韦林治疗 - Na'Ve，非抑菌HCV HCV基因型3感染患者
4. Interleukin-12 P40 (IL-12 B) Taq-1 Polymorphism association in pharmacogenomics of HCV genotype 3a infection from Pakistani population [C] . Zia-ur-Rehman Farooqi, Muhammad Sohail Afzal, Sadia Tahir, 2011 International Conference on Environmental, Biomedical and Biotechnology . 2011

机译：巴基斯坦人群HCV基因型3a感染的药物基因组学中白介素12 P40（IL-12 B）Taq-1多态性关联
5. Considerations Decision Makers Use to Decide Pharmacologic Treatment for Patients Infected with the Hepatitus C Virus (HCV) in State Prisons [D] . Castro, Juan. 2018

机译：决策者用于确定州监狱中感染丙型肝炎病毒（HCV）的患者的药物治疗注意事项
6. Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors [O] . Tatsuo Kanda, Shin Yasui, Masato Nakamura, 2017

机译：在丙型肝炎病毒基因型1感染的日本患者中联合应用Ledipasvir和Sofosbuvir治疗12周的真实经验：先前使用Peginterferon加利巴韦林与HCV NS3 / 4A抑制剂的使用者中获得了持续的病毒学应答
7. Virologic response at week 8 of combined treatment as a predictor of sustained virologic response in non rapid virologic response, chronic HCV genotype 4 infected patients [O] . Monis Ali, Ali Monis Ahmed, Al Swaff Reham 2012

机译：联合治疗第8周的病毒学应答可作为非快速病毒应答，慢性HCV基因型4型感染患者持续病毒应答的预测指标

PIN73 Estimating the cost-Effectiveness of 12 weeks of treatment with Daclatasvir+Sofosbuvir In Patients Chronically Infected With hcv Genotype 3

著录项

引文网络

相似文献

相关主题

期刊订阅